GlassScriptPhysician profile
Julie E Ayala
NPI 1952750291
$1,626.46
in general payments reported to CMS, 2019-2025
22 companies · $542 in 2025
The $542 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $146 · 2022: $245 · 2023: $403 · 2024: $291 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,235.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $218.96 | 2021-2023 | Orilissa, Lo Loestrin Fe |
| Astellas Pharma US INC | $180.44 | 2023-2025 | Veozah |
| Pfizer INC. | $168.93 | 2023-2025 | |
| Hologic Sales and Service, LLC | $166.05 | 2021-2025 | Novasure, Myosure Tissue Removal Device |
| Sumitomo Pharma America, INC. | $161.39 | 2023-2025 | Myfembree |
| Sage Therapeutics, LLC | $113.71 | 2024-2025 | Zurzuvae |
| Shield Therapeutics INC | $106.96 | 2022-2025 | |
| Gynesonics, INC. | $98.91 | 2022-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Mayne Pharma Commercial LLC | $73.42 | 2022-2025 | |
| Pacira Pharmaceuticals Incorporated | $63.49 | 2022-2024 | Exparel |
| Bayer Healthcare Pharmaceuticals INC. | $49.25 | 2023-2025 | |
| Exact Sciences Corporation | $33.23 | 2023-2025 | Cologuard Collection Kit |
| Myovant Sciences INC. | $30.77 | 2022 | |
| Organon LLC | $30.22 | 2022-2024 | |
| Integra Lifesciences Corporation | $20.39 | 2025 | Codman Hakim, Codman Certas, Cusa Clarity |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $17.50 | 2022 | |
| Novo Nordisk INC | $16.63 | 2023 | Wegovy |
| Supernus Pharmaceuticals, INC. | $16.61 | 2025 | Qelbree |
| Exeltis, USA INC. | $15.89 | 2024 | Slynd |
| Mimedx Group, INC. | $15.04 | 2025 | |
| Avion Pharmaceuticals | $14.88 | 2023 | Balcoltra |
| Medtronic, INC. | $13.79 | 2025 | Ligasure |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Ayala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.